Form 8-K bluebird bio, Inc. For: Aug 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
bluebird bio (BLUE) PT Lowered to $19 at Morgan Stanley
August 11, 2021 8:26 AM EDTMorgan Stanley analyst Matthew Harrison lowered the price target on bluebird bio (NASDAQ: BLUE) to $19.00 (from $35.00) while maintaining a Equalweight rating.
... MoreGoldman Sachs Downgrades bluebird bio (BLUE) to Neutral
August 10, 2021 6:56 AM EDTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Buy to Neutral with a price target of $23.00 (from $63.00).
The analyst comments "We downgrade BLUE from Buy to Neutral and lower our 12-month PT to $23 from $63. First, we note the newly announced clinical hold for gene therapy Lenti-D in cerebral adrenoleukodystrophy (CALD) due to a Suspected Unexpected Serious Adverse... More
bluebird bio (BLUE) PT Lowered to $18 at Stifel
August 9, 2021 1:56 PM EDTStifel analyst Benjamin J. Burnett lowered the price target on bluebird bio (NASDAQ: BLUE) to $18.00 (from $31.00) while maintaining a Hold rating.
The analyst commented, "We remain Hold rated on BLUE following two negative updates: (1) a patient treated with Lenti-D (Cerebral Adrenoleukodystrophy) developed... More
